{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:29:25Z","timestamp":1791822565473,"version":"4.3.4"},"reference-count":121,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100010574","name":"China Academy of Space Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010574","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["470188766"],"award-info":[{"award-number":["470188766"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG SFB 1425 \\u2013 ID 422681845"],"award-info":[{"award-number":["DFG SFB 1425 \\u2013 ID 422681845"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kisupplements.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Supplements"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.kisu.2021.11.001","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T05:02:07Z","timestamp":1647579727000},"page":"19-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms"],"prefix":"10.1016","volume":"12","author":[{"given":"Johann","family":"Bauersachs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Lother","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kisu.2021.11.001_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev-pharmtox-010814-124302","article-title":"Mineralocorticoids in the heart and vasculature: new insights for old hormones","volume":"55","author":"Lother","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.kisu.2021.11.001_bib2","doi-asserted-by":"crossref","first-page":"T35","DOI":"10.1530\/JOE-16-0669","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor and NaCl transport mechanisms in the renal distal nephron","volume":"234","author":"Shibata","year":"2017","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.kisu.2021.11.001_bib3","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.kisu.2021.11.001_bib4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kisu.2021.11.001_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2125.1999.00954.x","article-title":"Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?","volume":"47","author":"Struthers","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.kisu.2021.11.001_bib6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCRESAHA.120.317424","article-title":"Mineralocorticoid receptors: master regulators of extracellular matrix remodeling","volume":"127","author":"Lother","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.kisu.2021.11.001_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib8","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kisu.2021.11.001_bib9","first-page":"376","article-title":"The treatment of heart failure with reduced ejection fraction","volume":"117","author":"Berliner","year":"2020","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.kisu.2021.11.001_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.pharmthera.2016.07.004","article-title":"Pharmacology of heart failure: from basic science to novel therapies","volume":"166","author":"Lother","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.kisu.2021.11.001_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.001_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.001_bib13","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kisu.2021.11.001_bib14","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A\u00a0randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kisu.2021.11.001_bib15","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.kisu.2021.11.001_bib16","doi-asserted-by":"crossref","unstructured":"Asakura M, Ito S, Yamada T, et\u00a0al. Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicenter, randomized, double-blind, placebo-controlled trial. Eur Heart J Cardiovasc Pharmacother. 2022;8:108\u2013117.","DOI":"10.1093\/ehjcvp\/pvaa132"},{"key":"10.1016\/j.kisu.2021.11.001_bib17","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.001_bib18","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kisu.2021.11.001_bib19","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kisu.2021.11.001_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00392-018-1378-0","article-title":"Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials","volume":"108","author":"Rossello","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.kisu.2021.11.001_bib21","article-title":"Avoiding untimely implantable cardioverter\/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter\/defibrillator\u2013the PROLONG study","volume":"6","author":"Duncker","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.kisu.2021.11.001_bib22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/01.CIR.0000153800.09920.40","article-title":"Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload","volume":"111","author":"Kuster","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.001_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cardiores.2005.03.001","article-title":"Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction","volume":"67","author":"Fraccarollo","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.kisu.2021.11.001_bib24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.107.100941","article-title":"Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response","volume":"51","author":"Fraccarollo","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/HYPERTENSIONAHA.115.06709","article-title":"Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction","volume":"67","author":"Gueret","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib26","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.001_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1161\/HYPERTENSIONAHA.118.12162","article-title":"Macrophage mineralocorticoid receptor is a pleiotropic modulator of myocardial infarct healing","volume":"73","author":"Fraccarollo","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib28","article-title":"Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2021.11.001_bib29","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kisu.2021.11.001_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/HYPERTENSIONAHA.117.09070","article-title":"Mineralocorticoid receptor deficiency in T cells attenuates pressure overload-induced cardiac hypertrophy and dysfunction through modulating T-Cell activation","volume":"70","author":"Li","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007279","article-title":"Mineralocorticoid receptor in smooth muscle contributes to pressure overload-induced heart failure","volume":"14","author":"Kim","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.kisu.2021.11.001_bib32","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.110.163287","article-title":"Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function","volume":"57","author":"Lother","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib33","doi-asserted-by":"crossref","first-page":"e13313","DOI":"10.14814\/phy2.13313","article-title":"Endothelial mineralocorticoid receptor contributes to systolic dysfunction induced by pressure overload without modulating cardiac hypertrophy or inflammation","volume":"5","author":"Salvador","year":"2017","journal-title":"Physiol Rep"},{"key":"10.1016\/j.kisu.2021.11.001_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/HYPERTENSIONAHA.116.07418","article-title":"Vascular mineralocorticoid receptors: linking risk factors, hypertension, and heart disease","volume":"68","author":"Lother","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib35","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/HYPERTENSIONAHA.115.06015","article-title":"Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females","volume":"66","author":"Jia","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib36","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.113.01803","article-title":"Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone\/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure","volume":"63","author":"Rickard","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","article-title":"Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure","volume":"54","author":"Rickard","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib38","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1210\/en.2011-2098","article-title":"Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis","volume":"153","author":"Bienvenu","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.kisu.2021.11.001_bib39","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1161\/ATVBAHA.119.312954","article-title":"Endothelial mineralocorticoid receptors contribute to vascular inflammation in atherosclerosis in a sex-specific manner","volume":"39","author":"Moss","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kisu.2021.11.001_bib40","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1074\/jbc.M116.739243","article-title":"Mineralocorticoid receptor deficiency in macrophages inhibits atherosclerosis by affecting foam cell formation and efferocytosis","volume":"292","author":"Shen","year":"2017","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kisu.2021.11.001_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fcvm.2018.00081","article-title":"No significant role for smooth muscle cell mineralocorticoid receptors in atherosclerosis in the apolipoprotein-E knockout mouse model","volume":"5","author":"Moss","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.kisu.2021.11.001_bib42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/ATVBAHA.113.302854","article-title":"Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors","volume":"34","author":"Pruthi","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kisu.2021.11.001_bib43","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/ATVBAHA.115.307031","article-title":"Mineralocorticoid receptor deficiency in macrophages inhibits neointimal hyperplasia and suppresses macrophage inflammation through SGK1-AP1\/NF-kappaB pathways","volume":"36","author":"Sun","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kisu.2021.11.001_bib44","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/HYPERTENSIONAHA.115.06172","article-title":"Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure","volume":"66","author":"Barrett Mueller","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193032","article-title":"Endothelial mineralocorticoid receptor ablation does not alter blood pressure, kidney function or renal vessel contractility","volume":"13","author":"Laursen","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2021.11.001_bib46","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"McCurley","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.kisu.2021.11.001_bib47","doi-asserted-by":"crossref","first-page":"e88942","DOI":"10.1172\/jci.insight.88942","article-title":"Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging","volume":"1","author":"DuPont","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.kisu.2021.11.001_bib48","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1161\/HYPERTENSIONAHA.113.01967","article-title":"Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness","volume":"63","author":"Galmiche","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib49","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1161\/CIRCRESAHA.116.310480","article-title":"T-cell mineralocorticoid receptor controls blood pressure by regulating interferon-gamma","volume":"120","author":"Sun","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.kisu.2021.11.001_bib50","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1161\/HYPERTENSIONAHA.120.16196","article-title":"Eplerenone improves pulmonary vascular remodeling and hypertension by inhibition of the mineralocorticoid receptor in endothelial cells","volume":"78","author":"Kowalski","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib51","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/cvr\/cvx078","article-title":"Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity","volume":"114","author":"Lother","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.kisu.2021.11.001_bib52","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/HYPERTENSIONAHA.118.11544","article-title":"Regulation of atrial fibrosis by the bone","volume":"73","author":"Yi","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib53","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1161\/CIRCRESAHA.119.316427","article-title":"A\u00a0new role for the aldosterone\/mineralocorticoid receptor pathway in the development of mitral valve prolapse","volume":"127","author":"Ibarrola","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.kisu.2021.11.001_bib54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-18-0494","article-title":"Endothelial cell mineralocorticoid receptors oppose VEGF-induced gene expression and angiogenesis","volume":"240","author":"Lother","year":"2019","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.kisu.2021.11.001_bib55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jchf.2014.08.002","article-title":"The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries","volume":"3","author":"Calvier","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.kisu.2021.11.001_bib56","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/HYPERTENSIONAHA.115.05876","article-title":"Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension","volume":"66","author":"Martinez-Martinez","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/HYPERTENSIONAHA.115.05431","article-title":"Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids","volume":"66","author":"Tarjus","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.yjmcc.2017.12.011","article-title":"Neutrophil gelatinase-associated lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation","volume":"115","author":"Buonafine","year":"2018","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.kisu.2021.11.001_bib59","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/ejhf.1813","article-title":"MiRNA-181a is a novel regulator of aldosterone-mineralocorticoid receptor-mediated cardiac remodelling","volume":"22","author":"Garg","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kisu.2021.11.001_bib60","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-med-041316-090654","article-title":"Heart failure with preserved ejection fraction","volume":"69","author":"Gladden","year":"2018","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.kisu.2021.11.001_bib61","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A\u00a0novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kisu.2021.11.001_bib62","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jacbts.2017.07.013","article-title":"Murine models of heart failure with preserved ejection fraction: a \"fishing expedition.\"","volume":"2","author":"Valero-Munoz","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.kisu.2021.11.001_bib63","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/cvr\/cvz161","article-title":"Small animal models of heart failure","volume":"115","author":"Riehle","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.kisu.2021.11.001_bib64","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/HYPERTENSIONAHA.114.04912","article-title":"Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction","volume":"65","author":"Bender","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib65","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/ehf2.13219","article-title":"Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice","volume":"8","author":"Pieronne-Deperrois","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.kisu.2021.11.001_bib66","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.yjmcc.2018.06.008","article-title":"Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice","volume":"121","author":"Bonnard","year":"2018","journal-title":"J\u00a0Mol Cell Cardiol"},{"issue":"suppl 11","key":"10.1016\/j.kisu.2021.11.001_bib67","first-page":"S143","article-title":"Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system","volume":"10","author":"Brown","year":"1999","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2021.11.001_bib68","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1161\/HYPERTENSIONAHA.112.203158","article-title":"Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone\/salt-mediated inflammation and cardiac fibrosis","volume":"60","author":"Rickard","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib69","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.115.06530","article-title":"Deoxycorticosterone acetate\/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure","volume":"67","author":"Lother","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib70","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cardfail.2014.05.010","article-title":"Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction","volume":"20","author":"Kurrelmeyer","year":"2014","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.kisu.2021.11.001_bib71","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2016.07.763","article-title":"Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction","volume":"68","author":"Kosmala","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kisu.2021.11.001_bib72","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.kisu.2021.11.001_bib73","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.001_bib74","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT\u2014 new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.001_bib75","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.001_bib76","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.001_bib77","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kisu.2021.11.001_bib78","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting inflammation in atherosclerosis\u2014from experimental insights to the clinic","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.kisu.2021.11.001_bib79","article-title":"Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism","volume":"2","author":"McGraw","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.kisu.2021.11.001_bib80","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1093\/eurheartj\/eht095","article-title":"Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity","volume":"34","author":"Schafer","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kisu.2021.11.001_bib81","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/HYPERTENSIONAHA.115.05674","article-title":"Low-dose mineralocorticoid receptor blockade prevents western diet-induced arterial stiffening in female mice","volume":"66","author":"DeMarco","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib82","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00395-017-0643-0","article-title":"Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs","volume":"112","author":"Li","year":"2017","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.kisu.2021.11.001_bib83","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1161\/01.ATV.0000204635.75748.0f","article-title":"Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation","volume":"26","author":"Suzuki","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kisu.2021.11.001_bib84","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijcard.2017.01.013","article-title":"Essential role of ICAM-1 in aldosterone-induced atherosclerosis","volume":"232","author":"Marzolla","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.kisu.2021.11.001_bib85","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","article-title":"Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion","volume":"102","author":"Caprio","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.kisu.2021.11.001_bib86","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","article-title":"Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells","volume":"96","author":"Jaffe","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.kisu.2021.11.001_bib87","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1161\/ATVBAHA.111.229070","article-title":"Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways","volume":"31","author":"Newfell","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kisu.2021.11.001_bib88","first-page":"317","article-title":"Aldosterone induces trained immunity: the role of fatty acid synthesis","volume":"116","author":"van der Heijden","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.kisu.2021.11.001_bib89","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/cvr\/cvy092","article-title":"The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis","volume":"114","author":"van der Heijden","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.kisu.2021.11.001_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184888","article-title":"The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury","volume":"12","author":"Dutzmann","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2021.11.001_bib91","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.vph.2017.12.065","article-title":"Evidence for the use of mineralocorticoid receptor antagonists in the treatment of coronary artery disease and post-angioplasty restenosis","volume":"107","author":"Dutzmann","year":"2018","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.kisu.2021.11.001_bib92","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.001_bib93","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","article-title":"Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism","volume":"25","author":"Brilla","year":"1993","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.kisu.2021.11.001_bib94","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1172\/JCI117269","article-title":"Mineralocorticoids, hypertension, and cardiac fibrosis","volume":"93","author":"Young","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kisu.2021.11.001_bib95","doi-asserted-by":"crossref","first-page":"T67","DOI":"10.1530\/JOE-17-0009","article-title":"30 years of the mineralocorticoid receptor: the role of the mineralocorticoid receptor in the vasculature","volume":"234","author":"DuPont","year":"2017","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.kisu.2021.11.001_bib96","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13293-020-00340-5","article-title":"Selective deletion of endothelial mineralocorticoid receptor protects from vascular dysfunction in sodium-restricted female mice","volume":"11","author":"Faulkner","year":"2020","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.kisu.2021.11.001_bib97","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1096\/fj.09-147926","article-title":"The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure","volume":"24","author":"Nguyen Dinh Cat","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.kisu.2021.11.001_bib98","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1161\/HYPERTENSIONAHA.117.10437","article-title":"Smooth muscle cell-mineralocorticoid receptor as a mediator of cardiovascular stiffness with aging","volume":"71","author":"Kim","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib99","article-title":"Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis","volume":"99","author":"Chen","year":"2020","journal-title":"Med (Balt)"},{"key":"10.1016\/j.kisu.2021.11.001_bib100","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kisu.2021.11.001_bib101","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib102","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","article-title":"Esaxerenone: first global approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.kisu.2021.11.001_bib103","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD Study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.kisu.2021.11.001_bib104","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2021.11.001_bib105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/eurjhf\/hfs173","article-title":"Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study","volume":"15","author":"Maron","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kisu.2021.11.001_bib106","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/heartjnl-2015-308365","article-title":"Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension","volume":"102","author":"Calvier","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.kisu.2021.11.001_bib107","doi-asserted-by":"crossref","first-page":"L678","DOI":"10.1152\/ajplung.00300.2012","article-title":"Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension","volume":"304","author":"Preston","year":"2013","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.kisu.2021.11.001_bib108","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap7294","article-title":"NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension","volume":"10","author":"Samokhin","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.kisu.2021.11.001_bib109","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.001_bib110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12890-018-0604-x","article-title":"Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension","volume":"18","author":"Boehm","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.kisu.2021.11.001_bib111","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/CIRCULATIONAHA.113.007690","article-title":"Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis","volume":"130","author":"Maron","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.kisu.2021.11.001_bib112","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.amjcard.2013.04.051","article-title":"Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials)","volume":"112","author":"Maron","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.kisu.2021.11.001_bib113","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/cvr\/cvx162","article-title":"Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity","volume":"114","author":"Hullin","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.kisu.2021.11.001_bib114","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kisu.2021.11.001_bib115","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.kisu.2021.11.001_bib116","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.jacc.2017.10.014","article-title":"Eplerenone reduces atrial fibrillation burden without preventing atrial electrical remodeling","volume":"70","author":"Takemoto","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kisu.2021.11.001_bib117","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000471918","article-title":"Eplerenone prevents atrial fibrosis via the TGF-beta signaling pathway","volume":"138","author":"Du","year":"2017","journal-title":"Cardiology"},{"key":"10.1016\/j.kisu.2021.11.001_bib118","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/hr.2010.277","article-title":"Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats","volume":"34","author":"Kimura","year":"2011","journal-title":"Hypertens Res"},{"key":"10.1016\/j.kisu.2021.11.001_bib119","article-title":"Effects of mineralocorticoid receptor antagonists on atrial fibrillation occurrence: a systematic review, meta-analysis, and meta-regression to identify modifying factors","volume":"8","author":"Alexandre","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.kisu.2021.11.001_bib120","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S0140-6736(16)00558-4","article-title":"Mitral valve disease\u2014current management and future challenges","volume":"387","author":"Nishimura","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2021.11.001_bib121","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.3390\/ijms21155372","article-title":"Beneficial effects of mineralocorticoid receptor antagonism on myocardial fibrosis in an experimental model of the myxomatous degeneration of the mitral valve","volume":"21","author":"Ibarrola","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Kidney International Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171621000642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171621000642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:50:38Z","timestamp":1778838638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2157171621000642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2157171621000642"],"URL":"https:\/\/doi.org\/10.1016\/j.kisu.2021.11.001","relation":{},"ISSN":["2157-1716"],"issn-type":[{"value":"2157-1716","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms","name":"articletitle","label":"Article Title"},{"value":"Kidney International Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2021.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}